Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

A cAMP-Dependent, Protein Kinase A-Independent Signaling Pathway Mediating Neuritogenesis through Egr1 in PC12 Cells

Aurélia Ravni, David Vaudry, Matthew J. Gerdin, Maribeth V. Eiden, Anthony Falluel-Morel, Bruno J. Gonzalez, Hubert Vaudry and Lee E. Eiden
Molecular Pharmacology June 2008, 73 (6) 1688-1708; DOI: https://doi.org/10.1124/mol.107.044792
Aurélia Ravni
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Vaudry
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew J. Gerdin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maribeth V. Eiden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Falluel-Morel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno J. Gonzalez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hubert Vaudry
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lee E. Eiden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The neurotrophic peptide PACAP (pituitary adenylate cyclase-activating polypeptide) elevates cAMP in PC12 cells. Forskolin and dibutyryl cAMP mimic PACAP's neuritogenic and cell morphological effects, suggesting that they are driven by cAMP. Comparison of microarray expression profiles after exposure of PC12 cells to either forskolin, dibutyryl cAMP, or PACAP revealed a small group of cAMP-dependent target genes. Neuritogenesis induced by all three agents is protein kinase A (PKA)-independent [not blocked by N-[2-(4-bromocinnamylamino)ethyl]-5-isoquinoline (H89)] and extracellular signal-regulated kinase (ERK)-dependent [blocked by 1,4-diamino-2,3-dicyano-1,4-bis(methylthio) butadiene (U0126)], and therefore cAMP-dependent target genes potentially mediating neuritogenesis were selected for further analysis based on the pharmacological profile of their induction by PACAP (i.e., mimicking that of neuritogenesis). Small interfering RNA (siRNA) targeting one of these genes, Egr1, blocked PACAP-induced neuritogenesis, and siRNA targeting another, Vil2, blocked a component of the cell size increase elicited by PACAP. Neither siRNA blocked PACAP's PKA-dependent antiproliferative effects. PACAP signaling to neuritogenesis was also impaired by dominant-negative Rap1 expression but was not affected by inhibition of protein kinase C (PKC), indicating a G-protein-coupled receptor-mediated differentiation pathway distinct from the one activated by receptor tyrosine kinase ligands such as nerve growth factor (NGF), that involves both Rap1 and PKC. We have thus identified a cAMP-dependent, PKA-independent pathway proceeding through ERK that functions to up-regulate the transcription of two genes, Egr1 and Vil2, required for PACAP-dependent neuritogenesis and increased cell size, respectively. Dominant-negative Rap1 expression impairs both PACAP-induced neuritogenesis and Egr1 activation by PACAP, suggesting that cAMP elevation and ERK activation by PACAP are linked through Rap1.

Footnotes

  • This work was funded by the National Institute of Mental Health (NIMH) Intramural Research Program Project 1Z01-MH002386-20, Institut National de la Santé et de la Recherche Médicale (U413), the European Institute for Peptide Research (l'Institut Fédératif de Recherches Multidisciplinaires sur les Peptides 23), the Association pour la Recherche sur le Cancer and the Conseil Régional de Haute-Normandie. A.R. was the recipient of a doctoral fellowship from the Ministry of Education.

  • ABBREVIATIONS: NGF, nerve growth factor; dbcAMP, N6,2′-O-dibutyryladenosine 3′,5′-cyclic monophosphate; ddAd, 2′,5′-dideoxyadenosine; Egr1, early growth response 1; ERK, extracellular signal-regulated protein kinase; Gapdh, glyceraldehyde-3-phosphate dehydrogenase; GST, glutathione transferase; H7, 1-(5-Isoquinolinesulfonyl)-2-methylpiperazine; H89, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide dihydrochloride; Ier3, immediate early response 3; IRES, internal ribosome entry site; MAP, mitogen-activated protein; MEK, mitogen-activated protein kinase kinase; PAC1, PACAP specific receptor; PACAP, pituitary adenylate cyclase-activating polypeptide; PCR, polymerase chain reaction; PD98059, 2′-amino-3′-methoxyflavone; PKA, protein kinase A; PKC, protein kinase C; PLC, phospholipase C; Q-RT-PCR, quantitative reverse transcription-polymerase chain reaction; Rap1, member of RAS oncogene family; RBD, Rap binding domain; RT-PCR, reverse transcription-polymerase chain reaction; siRNA, small interfering RNA; SSC, saline-sodium citrate; U0126, 1,4-diamino-2,3-dicyano-1,4-bis(methylthio-)butadiene; Vil2, villin 2; VIP, vasoactive intestinal polypeptide; VPAC, PACAP and VIP receptor

    • Received January 2, 2008.
    • Accepted March 17, 2008.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 73 (6)
Molecular Pharmacology
Vol. 73, Issue 6
1 Jun 2008
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A cAMP-Dependent, Protein Kinase A-Independent Signaling Pathway Mediating Neuritogenesis through Egr1 in PC12 Cells
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

A cAMP-Dependent, Protein Kinase A-Independent Signaling Pathway Mediating Neuritogenesis through Egr1 in PC12 Cells

Aurélia Ravni, David Vaudry, Matthew J. Gerdin, Maribeth V. Eiden, Anthony Falluel-Morel, Bruno J. Gonzalez, Hubert Vaudry and Lee E. Eiden
Molecular Pharmacology June 1, 2008, 73 (6) 1688-1708; DOI: https://doi.org/10.1124/mol.107.044792

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

A cAMP-Dependent, Protein Kinase A-Independent Signaling Pathway Mediating Neuritogenesis through Egr1 in PC12 Cells

Aurélia Ravni, David Vaudry, Matthew J. Gerdin, Maribeth V. Eiden, Anthony Falluel-Morel, Bruno J. Gonzalez, Hubert Vaudry and Lee E. Eiden
Molecular Pharmacology June 1, 2008, 73 (6) 1688-1708; DOI: https://doi.org/10.1124/mol.107.044792
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Analgesic Effects and Mechanisms of Licochalcones
  • Induced Fit Ligand Binding to CYP3A4
  • Englerin A Inhibits T-Type Channels
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics